DOK3

Across TCGA pan-cancer cohorts, DOK3 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DOK3 data layer compared with 25 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher DOK3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated DOK3 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

MESO, COAD, and UCEC are the cancer types where DOK3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	DFS	Median	All	0.101	0.632	.011	3	view →
LUSC	DFS	Median	All	1.000	0.654	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DOK3–MESO (DFS)

Open the MESO breakdown →